Trials / Completed
CompletedNCT00591188
Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
Phase II Study of Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- Sponsor
- Kidney Cancer Research Bureau · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to determine preliminary efficacy of capecitabine and interferon-alpha in second-line after interleukin-2 based regimens in patients with MRCC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | capecitabine, interferon-alpha | Patients who meet inclusion/exclusion criteria will receive combination of study drugs. |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2008-05-01
- First posted
- 2008-01-11
- Last updated
- 2009-05-01
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT00591188. Inclusion in this directory is not an endorsement.